Loading
institutionsInstitution
BC Cancer
British Columbia's provincial cancer agency, a world leader in cancer genomics (Personalized OncoGenomics), lymphoma research and HPV-based cervical screening.
Also called: BC Cancer AgencyBritish Columbia Cancer Agency
Overview
BC Cancer, part of the Provincial Health Services Authority, delivers cancer care through six regional centres and runs the province's screening programmes and registry. Its Michael Smith Genome Sciences Centre under Marco Marra launched the Personalized OncoGenomics programme in 2012, one of the first to sequence whole genomes and transcriptomes of patients' tumours to guide therapy. Sam Aparicio co-led METABRIC and pioneered single-cell genomics of breast cancer; David Huntsman's OVCARE group discovered ARID1A mutations in clear-cell ovarian cancer; Randy Gascoyne, Christian Steidl and Joseph Connors built one of the world's leading lymphoma programmes, including co-leadership of ECHELON-1 for brentuximab vedotin in Hodgkin lymphoma. Gina Ogilvie's HPV FOCAL trial helped move BC to HPV-based primary cervical screening, and Connie Eaves's Terry Fox Laboratory shaped stem cell biology.
Location
Vancouver, BC, CA
Type
cancer center · University of British Columbia
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#119 · 36 points (0 Newsweek + 0 NCI + 36 from 18 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to BC Cancer Agency, including child institutions. 305 works · 2,733 citations · 70% open access · 10% clinical trials · 2% reviews.
Oncology works per year
522022
672023
592024
862025
412026
Most works
- Jonathan M. Loree24 works
- Daniel J. Renouf17 works
- Sharlene Gill14 works
- Janessa Laskin14 works
- Nathalie LeVasseur13 works
- Renata D’Alpino Peixoto12 works
- Poul H. Sorensen11 works
- Kristin L. Campbell11 works
- Cheryl Ho10 works
- Dongsheng Tu10 works
Most cited
- Personalized OncoGenomics
- Lymphoma
- Ovarian cancer (OVCARE)
- HPV-based cervical screening
- Terry Fox Laboratory
Joseph M. Connors
Clinical Professor Emeritus, BC Cancer Centre for Lymphoid Cancer, University of British Columbia
Hodgkin lymphomaPopulation-based lymphoma careAntibody-drug conjugates
Led ECHELON-1, which replaced bleomycin with brentuximab vedotin in first-line advanced Hodgkin lymphoma.
Kim N. Chi
Medical Oncologist and Chief Medical Officer, BC Cancer; Professor, University of British Columbia
Prostate cancerAndrogen receptor inhibitorsPARP inhibitor combinations
Led TITAN and MAGNITUDE, bringing apalutamide to hormone-sensitive disease and niraparib to HRR-mutant prostate cancer.
Laurie H. Sehn
Chair, Lymphoma Tumour Group, BC Cancer; Clinical Professor, University of British Columbia
Diffuse large B-cell lymphomaPopulation-based outcomesNovel agents
Lymphoma specialist who wrote the definitive DLBCL review and helped establish polatuzumab and other new agents.
Paris-Ann Ingledew
Executive Vice President and Chief Medical Officer, BC Cancer
Radiation oncologyMedical educationHealth leadership
Radiation oncologist and educator who is the executive lead for BC Cancer, the provincial cancer agency of British Columbia, Canada.
translationalClinical Cancer Research 202146 citations
Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics
A subtype report should carry a confidence, and a trial that dichotomises subtype will misplace about one patient in eight.
translationalClinical Cancer Research 2019changed practice132 citations
Jones 2019: NRG1 gene fusions are recurrent, clinically actionable rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma
Together with the German MASTER report, this paper is why guidelines recommend comprehensive profiling with fusion detection in KRAS wild-type pancreatic cancer.
Similar pages
- InstitutionShizuoka Cancer Center
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, RNA sequencing & expression profiling, Whole-exome & whole-genome sequencing, Proton therapy.
- TrialECHELON-1
Shares Joseph M. Connors, Brentuximab vedotin, Hodgkin lymphoma.
- Key paperECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma
Shares Joseph M. Connors, Brentuximab vedotin, Hodgkin lymphoma.
- PersonCarlos Caldas
Shares RNA sequencing & expression profiling, Whole-exome & whole-genome sequencing, HR-positive / HER2-negative breast cancer.
- CompanyHologic
Shares HPV DNA testing and self-sampling, Cervical cancer, HR-positive / HER2-negative breast cancer.
- PersonAlex F. Herrera
Shares Brentuximab vedotin, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- InstitutionApollo Hospitals (Apollo Cancer Centres)
Shares Proton therapy machines: cyclotrons, synchrotrons and single-room systems, Proton therapy, HR-positive / HER2-negative breast cancer.
- IdeaMeasure the late effects of the treatments being given now, not the ones given in 1975
Shares Brentuximab vedotin, Proton therapy, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
cancers
fronts
technologies
drugs
ApprovedADC
Brentuximab vedotin · Adcetris